Cullinan Therapeutics (CGEM, $18.89) was one of top quarterly gainers, jumping +4 to $18.89 per share. A.I.dvisor analyzed 914 stocks in the Biotechnology Industry over the last three months, and discovered that of them (4) charted an Uptrend while of them (5) trended down. A.I.dvisor found 58 similar cases when CGEM's price went up within three months. In out of those 58 cases, CGEM's price went down during the following month. Based on these historical data, A.I. thinks the odds of an Uptrend reversal for CGEM are